BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
Neurology/psychiatric RSS Feed RSS

Neurology/Psychiatric

Sichuan Haisco Pharmaceutical patents AAK1 inhibitors for diabetic neuropathy and postherpetic neuralgia

Feb. 10, 2023
Sichuan Haisco Pharmaceutical Co. Ltd. has disclosed AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of diabetic neuropathy and postherpetic neuralgia.
Read More
Illustration of neuron, synapse.
Neurology/Psychiatric

Synapse organizers LRRTM1 and SynCAM 1 have concerted roles in the prefrontal cortex of mice

Feb. 10, 2023
Trans-synaptic complexes regulate synapse development and maturation. Disorders involving synaptopathies, such as schizophrenia, affect specific regions of the brain.
Read More
Cross-section of brain
Neurology/Psychiatric

circSCMH1 promotes vascular repair after stroke through FTO-regulated methylation

Feb. 10, 2023
Circular RNAs (circRNAs) are non-coding RNAs abundant in the brain, and several of them are functionally involved in ischemic stroke.
Read More
Tree in the shape of human head losing leaves
Neurology/Psychiatric

Much remains mysterious about cognitive decline

Feb. 10, 2023
By Anette Breindl
The shunt towards, or away from, cognitive decline may happen decades before such decline becomes clinically evident. And known risk factors explain very little of that decline. That is the conclusion reached by researchers from the Ohio State University, who published their results in the Feb. 8, 2023, issue of PLOS ONE.

In their analysis, the team looked at both the absolute level of cognitive function in about 7,000 participants of the U.S. Health and Retirement Study at age 54, and at the decline in cognitive function from age 54 to 85. The study participants that were analyzed were born between 1931 and 1941. The results were reminiscent of the adage that the way to make a silk purse out a sow’s ear is to start with a silk sow.
Read More
Neurology/Psychiatric

Denali Therapeutics patents new NLRP3 inflammasome inhibitors

Feb. 9, 2023
Denali Therapeutics Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of stroke, gout, multiple sclerosis, Alzheimer's disease, hypertension, silicosis, graft-versus-host disease and nonalcoholic steatohepatitis (NASH).
Read More
Illustration of motor neuron connecting to muscle fiber
Neurology/Psychiatric

Targeting coregulators of polyQ-expanded androgen receptor attenuates the SBMA phenotype in animal models

Feb. 9, 2023
Spinal-bulbar muscular atrophy (SBMA), also called Kennedy disease, is an X-linked genetic disorder in which the loss of motor neurons affects the parts of the nervous system that control voluntary muscle movement.
Read More

Woebot happy to enroll first patient in postpartum depression trial

Feb. 8, 2023
By Annette Boyle
Woebot Labs Inc. posted uplifting news for women who have suffered from baby blues and their big brother, post-partum depression. The company recently enrolled the first patient in its pivotal trial of WB001, a digital therapeutic for post-partum depression (PPD). WB001 received U.S. FDA breakthrough device designation in 2021, indicating the acute need for accessible treatment for the common condition.
Read More
Neurons
Neurology/Psychiatric

Shanghai Institute of Materia Medica describes new GPR84 antagonists

Feb. 8, 2023
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has identified G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of multiple sclerosis, inflammatory bowel disease, fibrosis, neurodegenerative disease and arthritis.
Read More
Multiple sclerosis
Neurology/Psychiatric

Canadian clearance for phase I trial of Lucid-MS for multiple sclerosis

Feb. 8, 2023
FSD Pharma Inc. has received a no objection letter (NOL) from Health Canada granting regulatory approval to commence a phase I trial of LUCID-21-302 (Lucid-MS), a novel drug candidate for the treatment of multiple sclerosis (MS).
Read More
Man sitting on bed holding head

Voice Health uses AI to diagnose depression from speech

Feb. 7, 2023
By Zhang Mengying
Artificial intelligence (AI) startup Voice Health Tech has developed a model that can diagnose depression.
Read More
Previous 1 2 … 312 313 314 315 316 317 318 319 320 … 3028 3029 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Microscopic image of chronic myeloid leukemia

    Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

    BioWorld
    Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing